XML 83 R49.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Details)
12 Months Ended
Dec. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
Feb. 09, 2023
$ / shares
Summary of Significant Accounting Policies [Line Items]      
Impairment of equity method investment $ 454,679  
Equity method investment 10,636,544 12,095,020  
Exceed federally-insured limits 250,000    
Federally insured limits 2,413,000    
Deferred offering costs 0 175,136  
Deferred rental income 38,346 11,429  
Advertising and marketing costs $ 237,671 $ 1,666,721  
Common stock, conversion price (in Dollars per share) | $ / shares $ 11.25 $ 22.5  
Percentage of purchase     40.00%
Reverse stock split 1-for-15    
Pre-Funded Warrants [Member]      
Summary of Significant Accounting Policies [Line Items]      
Warrants outstanding (in Shares) | shares 150,000    
RMB [Member]      
Summary of Significant Accounting Policies [Line Items]      
Foreign currency exchange rate 7.1889 7.0752  
United States [Member]      
Summary of Significant Accounting Policies [Line Items]      
Foreign currency exchange rate   1  
Common Stock [Member]      
Summary of Significant Accounting Policies [Line Items]      
Common stock, conversion price (in Dollars per share) | $ / shares   $ 67.5  
Equity Method Investment [Member]      
Summary of Significant Accounting Policies [Line Items]      
Impairment charges $ 259,579 $ 9,651,361  
Laboratory Services MSO, LLC [Member]      
Summary of Significant Accounting Policies [Line Items]      
Equity method investment 259,579 9,196,682  
Laboratory Equipment [Member]      
Summary of Significant Accounting Policies [Line Items]      
Impairment of equity method investment $ 111,033    
Business Combination [Member]      
Summary of Significant Accounting Policies [Line Items]      
Asset acquisition percentage 40.00%    
Research and Development Expense [Member]      
Summary of Significant Accounting Policies [Line Items]      
Research and development expense $ 0 109,618  
Epicon Biotech Co., Ltd [Member]      
Summary of Significant Accounting Policies [Line Items]      
Impairment of equity method investment   454,679  
Equity method investment   $ 0  
Dr. Yu Zhou [Member]      
Summary of Significant Accounting Policies [Line Items]      
Equity interest percent 40.00%    
Asset and liability Accounts [Member] | RMB [Member]      
Summary of Significant Accounting Policies [Line Items]      
Foreign currency exchange rate 7.298 7.0786  
Asset and liability Accounts [Member] | United States [Member]      
Summary of Significant Accounting Policies [Line Items]      
Foreign currency exchange rate   1  
Series A Convertible Preferred Stock [Member]      
Summary of Significant Accounting Policies [Line Items]      
Preferred stock, convertible conversion price (in Dollars per share) | $ / shares $ 150    
Series B Convertible Preferred Stock [Member]      
Summary of Significant Accounting Policies [Line Items]      
Preferred stock, convertible conversion price (in Dollars per share) | $ / shares 56.7   $ 56.7
Common stock, conversion price (in Dollars per share) | $ / shares 56.7    
Series C Convertible Preferred Stock [Member]      
Summary of Significant Accounting Policies [Line Items]      
Preferred stock, convertible conversion price (in Dollars per share) | $ / shares $ 2.41